Purpose: To characterize the magnitude, timescale, and reliability of changes in functional and systemic outcome markers following moderate (MIR) and high (HIR) isoinertial resistance flywheel squat protocols (FSP).
Methods: Twenty-four resistance-trained males completed two exercise trials (ET1 & ET2) separated by 32 days. Functional and systemic markers were assessed at pre-exercise (PRE), immediately post-exercise (IP), and 24 (24H), 48 (48H), and 72 (72H) hours post-exercise. Three-way group x trial x time repeated measures ANOVAs were conducted to compare all dependent variables between groups (MIR & HIR) and experimental trials across time. Test-retest reliability between trials was assessed using intraclass correlation coefficients (ICC).
Results: At IP, both groups exhibited significantly decreased active range of motion, perceived recovery status, squat maximal voluntary isometric contraction force, and vertical jump performance, along with significantly increased muscle thickness and echo intensity (ultrasound), muscle soreness, and creatine kinase when compared to PRE. Most outcomes remained perturbed at 24H and 48H, especially in the HIR group. By 72H, only a subset of variables remained significantly changed from PRE. No significant attenuation of outcomes between trials were observed and test-retest reliability between trials was excellent for the FSP and moderate to excellent for most outcomes in both groups.
Conclusion: Our findings indicate that the FSP is a robust and repeatable exercise stimulus capable of eliciting significant exercise-induced muscle damage and reliable subsequent perturbations to functional and systemic markers of muscle damage. Our findings also support the use of crossover designs in future EIMD research designs with resistance-trained men.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s00421-024-05656-3 | DOI Listing |
Mol Med
December 2024
Department of Rheumatology and Immunology, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, P.R. China.
Background: ADAM19 (ADAM Metallopeptidase Domain 19) is known to be involved in extracellular matrix (ECM) remodeling, yet its specific function in systemic sclerosis (SSc) fibrosis remains unclear.
Objectives: This study sought to clarify the role and underlying mechanism of ADAM19 in SSc skin fibrosis.
Methods: The expression of ADAM19 was assessed in skin tissues of SSc and wound healing using publicly available transcriptome datasets.
Methods Mol Biol
December 2024
Institute for Biomedical Technologies - National Research Council (ITB-CNR), Segrate, Milan, Italy.
Amyloidosis diseases are characterized by protein misfolding, which forms insoluble beta-sheet fibrils progressively deposited in tissues. Deposition in the form of amyloid aggregates can occur in various organs, damaging their structure and function. The hallmark of amyloidosis is aberrant interactions leading to protein aggregation and proteotoxicity.
View Article and Find Full Text PDFNat Commun
December 2024
Department of Materials Science and Engineering, Korea University, Seoul, Republic of Korea.
The native extracellular matrix is continuously remodeled to form complex interconnected network structures that reversibly regulate stem cell behaviors. Both regulation and understanding of its intricate dynamicity can help to modulate numerous cell behaviors. However, neither of these has yet been achieved due to the lack of designing and modeling such complex structures with dynamic controllability.
View Article and Find Full Text PDFAutoimmunity
December 2025
Department of Clinical Immunology & Allergy, Westmead Hospital & ICPMR, Westmead, NSW, Australia.
Systemic lupus erythematosus (SLE) is an extremely heterogenous autoimmune disorder. A key biomarker, the double stranded (ds) DNA autoantibody, provides diagnostic specificity for SLE. We analyzed anti-dsDNA by mass spectrometry (MS) to determine if ascertaining the autoantibody's heavy chain variable region (IGHV) may hold any clinical relevance.
View Article and Find Full Text PDFLupus
December 2024
Department of Rheumatology and Immunology, Tangdu Hospital, Air Force Medical University, Xi'an, Shaanxi, China.
Objective: Despite some study demonstrated the effectiveness of telitacicept in patients with systemic lupus erythematosus (SLE), a noticeable gap exists in real-world data. This study aimed to examine the effectiveness and safety of telitacicept in patients with SLE in the real-world.
Method: This retrospective study enrolled patients with SLE at the Tangdu Hospital from January 2022 to January 2023.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!